Ohio State Navbar

Sign In

Robert J. Lee, PhD

Professor of Pharmaceutics
College of Pharmacy
Division of Pharmaceutics (Chair: Tom Schmittgen)
Other affiliations:  Joint appointment in the Department of Biomedical Engineering, member of the OSUCCC and NSEC, faculty member of the MCDB program, member of CCTS
Phone: (614) 292-4172
Email: lee.1339@osu.edu

 
 
 
Research in my lab is focused on targeted drug delivery systems based on nanoparticles. Nanoparticles can serve as carriers of therapeutic agents, including nucleic acids such as siRNA, miRNA and anti-miRs, and facilitate their therapeutic delivery.  Our effort is focused on improving nanoparticle composition based on rational design and directed at clinical applications. My lab closely collaborates with labs at the OSU Medical Center and is currently working on a number of disease targets.
 
Research Interests
Nanoparticle design and synthesis
Developing targeted multifunctional nanoparticles
Therapeutic delivery of oligonucleotides, including antisense ODNs, siRNA, miR and anti-miR
Clinical translation of nanoparticles
 
Selected Publications 
Zhou C, Mao Y, Sugimoto Y, Zhang Y, Kanthamneni N, Yu B, Brueggemeier RW, Lee LJ, Lee RJ. SPANosomes as delivery vehicles for small interfering RNA (siRNA). Mol Pharm. 2012;9:201-210.
 
Zhang Y, Zhou C, Kwak KJ, Wang X, Yung B, Lee LJ, Wang Y, Wang PG, Lee RJ. Efficient siRNA delivery using a polyamidoamine dendrimer with a modified pentaerythritol core. Pharm Res. 2012;29:1627-1636.
 
Zhou C, Zhang Y, Lee LJ, Lee RJ. Synthesis and characterization of lipoidal amine-based nanocarrier formulations for small interfering RNA delivery. Ther Deliv. 2012;3:715-723.
 
Piao L, Li H, Teng L, Yung BC, Sugimoto Y, Brueggemeier RW, Lee RJ. Human serum albumin coated lipid nanoparticles for delivery of siRNA to breast cancer. Nanomedicine. 2013;9:122-129.
 
Terp MC, Bauer F, Sugimoto Y, Yu B, Brueggemeier RW, Lee LJ, Lee RJ. Differential efficacy of DOTAP enantiomers for siRNA delivery in vitro. Int J Pharm. 2012;430:328-334.
 
Yu B, Hsu SH, Zhou C, Wang X, Terp MC, Wu Y, Teng L, Mao Y, Wang F, Xue W, Jacob ST, Ghoshal K, Lee RJ, Lee LJ. Lipid nanoparticles for hepatic delivery of small interfering RNA. Biomaterials. 2012;33:5924-5934.
 
Zhou X, Zhang M, Yung BC, Li H, Zhou C, Lee LJ, Lee RJ. Lactosylated liposomes for targeted doxorubicin delivery to hepatocellular carcinoma. Int J Nanomed. 2012;7: 5465-5474.
 
Mishra A, Liu S, Sams GH, Curphey DP, Santhanam R, Rush LJ, Schaefer D, Falkenberg LG, Sullivan L, Jaroncyk L, Yang X, Fisk H, Wu L-C, Chander JC, Wu YZ, Heerema NA, Chan KK, Perrottti D, Zhang J, Porcu P, Racke FK, Garzon R, Lee RJ, Marcucci G, Caligiuri MA. Aberrant Overexpression of IL-15 Initiates Large Granular Lymphocyte Leukemia through Chromosomal Instability and DNA Hypermethylation. Cancer Cell. 2012;22(5):645-55.
 
Yu B, Mao Y, Bai LY, Herman SEM, Ramanunni A, Mo X, Jin Y, Carolyn C, Chan KK, Jarjoura D, Marcucci G, Lee RJ, Byrd JC, Lee LJ, Muthusamy N. Targeted Nanoparticle Delivery Overcomes Off-Target Immunostimulatory Effects of Oligonucleotide and Improves Therapeutic Efficacy in Chronic Lymphocytic Leukemia. Blood. 2013;121:136-147.
 
Mao Y, Triantafillou G, Hertlein E, Towns WH, Stefanovski M, Mo X, Jarjoura D, Phelps MA, Marcucci G, Lee, LJ, Goldenberg DM, Lee RJ, Byrd, JC, Muthusamy N. Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carrier for Therapeutic Delivery in CD74+ B-Cell Malignancies. Clin Cancer Res. 2012;19:347-356.